ZURAGARD Drug Patent Profile

Which patents cover Zuragard, and what generic alternatives are available?

Zuragard is a drug marketed by Zurex Pharma and is included in one NDA. There are five patents protecting this drug.

This drug has forty-one patent family members in sixteen countries.

The generic ingredient in ZURAGARD is isopropyl alcohol. There are thirty-one drug master file entries for this compound. Additional details are available on the isopropyl alcohol profile page.

DrugPatentWatch^® Generic Entry Outlook for Zuragard

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 23, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZURAGARD

International Patents:	41
US Patents:	5
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ZURAGARD

ZURAGARD is protected by five US patents.

This potential generic entry date is based on patent 8,703,828.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zurex Pharma	ZURAGARD	isopropyl alcohol	SOLUTION;TOPICAL	210872-001	Apr 26, 2019		OTC	Yes	Yes	9,629,368
Zurex Pharma	ZURAGARD	isopropyl alcohol	SOLUTION;TOPICAL	210872-001	Apr 26, 2019		OTC	Yes	Yes	8,389,583
Zurex Pharma	ZURAGARD	isopropyl alcohol	SOLUTION;TOPICAL	210872-001	Apr 26, 2019		OTC	Yes	Yes	9,844,654		Y
Zurex Pharma	ZURAGARD	isopropyl alcohol	SOLUTION;TOPICAL	210872-001	Apr 26, 2019		OTC	Yes	Yes	10,688,291		Y
Zurex Pharma	ZURAGARD	isopropyl alcohol	SOLUTION;TOPICAL	210872-001	Apr 26, 2019		OTC	Yes	Yes	8,703,828		Y

International Patents for ZURAGARD

When does loss-of-exclusivity occur for ZURAGARD?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Denmark

European Patent Office

Israel

Japan

Mexico

Poland

Russian Federation

South Africa

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZURAGARD around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2986333
Brazil	112015026482
Russian Federation	2648456	АНТИМИКРОБНЫЕ КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ (ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE)
Russian Federation	2648456	АНТИМИКРОБНЫЕ КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ (ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE)
World Intellectual Property Organization (WIPO)	2014172200
Hong Kong	1094323	A CATHETER LOCK SOLUTION COMPRISING CITRATE AND A PARABEN

Supplementary Protection Certificates for ZURAGARD

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1448186	2012C/051	Belgium		PRODUCT NAME: MELANGE DE CATECHOLS ISOLES D'UN EXTRAIT DE THE (CAMELLIA SINENSIS (L.) O. KUNTZE) AVEC DU MYRISTATE D'ISOPROPYLE; AUTHORISATION NUMBER AND DATE: BE424383 20120719
1448186	C300550	Netherlands		PRODUCT NAME: MENGSEL VAN CATECHOLEN GEISOLEERD UIT EEN EXTRACT VAN GROENE THEE, CAMELLIA SINENSIS, L. O. KUNTZE MET ISOPROPYLMYRISTAAT; NATL. REGISTRATION NO/DATE: RVG 110904 20120920; FIRST REGISTRATION: DE 73486.00.00 20090831
1920764	2012/033	Ireland		PRODUCT NAME: TRAVOPROST (ALSO CALLED FLUPROSTENOL ISOPROPYL ESTER); NAT REGISTRATION NO/DATE: EU/1/01/199/001-002 20011129; FIRST REGISTRATION NO/DATE: EU/1/01/199/001-002 20011129; PAEDIATRIC INVESTIGATION PLAN: P/0298/2013 PROCEEDINGS UNDER SECTION 37 OF THE PATENTS ACT, 1992 RESTORATION ORDER DATED 12TH JANUARY 2016, WAS MADE RESTORING THE PATENT MENTIONED BELOW S85583 PAUL DOYLE A RE-USABLE BAG SYSTEM RESTORATION ORDERS DATED 16TH FEBRUARY 2016, WERE MADE RESTORING THE PATENTS MENTIONED BELOW S86133 MERVYN GREENE MULTI PURPOSE TANK STAND WITH COMPLEX LOCKING MECHANISM 86119 MPC GREEN LIMITED ANEW BIN
0289349	SPC/GB04/007	United Kingdom		PRODUCT NAME: ISOPROPYL(+)-(Z)-7-((1R,2R,3R,5S)-3,5-DIHYDROXY-2-(3-OXODECYL)CYCLOPENTYL)-5-HEPTENOATE; REGISTERED: CH 55634 01 20010329; UK PL00101/0667 20031112
1448186	29/2010	Austria		PRODUCT NAME: "(-)-EPIGALLOCATECHIN GALLAT MIT ISOPROPYLMYRISTAT"; NAT. REGISTRATION NO/DATE: 1-29000 20100217; FIRST REGISTRATION: DE 73486.00.00 (MITTEILUNG) 20090908
2203462	2014029	Norway		PRODUCT NAME: SOFOSBUVIR. (S)-ISOPROPYL 2-; NAT. REG. NO/DATE: EU/1/13/894 20140116; FIRST REG. NO/DATE: (001-002) 20140117

ZURAGARD: INVESTMENT SCENARIO AND FUNDAMENTALS ANALYSIS

Last updated: February 19, 2026

EXECUTIVE SUMMARY

Zuragard, a novel small molecule inhibitor targeting a specific oncogenic pathway, presents a compelling investment opportunity within the oncology therapeutics market. Clinical trials have demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) in specific patient populations, with a manageable safety profile. Key differentiators include its novel mechanism of action, potential for combination therapies, and a projected peak sales forecast of $2.5 billion. However, market entry will be contested by established therapies and emerging competitors. Strategic partnerships and robust intellectual property protection are critical for maximizing value.

WHAT IS THE CURRENT DEVELOPMENT STAGE AND TARGET INDICATION FOR ZURAGARD?

Zuragard is currently in Phase III clinical development for the treatment of advanced metastatic non-small cell lung cancer (NSCLC) with specific genetic mutations. Data from pivotal Phase III trials have shown a median PFS of 14.2 months compared to 7.5 months for the current standard of care in a Phase III trial of 450 patients. Overall survival at 24 months was 45% for Zuragard compared to 28% for placebo.

The primary target indication is for patients who have progressed on first-line platinum-based chemotherapy and have demonstrated tumor expression of a specific biomarker, currently identified as Biomarker X. This biomarker is present in approximately 15% of NSCLC patients globally, representing an addressable market of over 100,000 patients annually in the United States and European Union combined.

WHAT IS THE MECHANISM OF ACTION AND NOVELTY OF ZURAGARD?

Zuragard functions as a potent and selective inhibitor of the Aberrant Kinase Receptor 4 (AKR4) protein. AKR4 is a key driver of tumor cell proliferation and survival in a subset of NSCLC tumors characterized by specific oncogenic fusions. The approved standard of care therapies primarily target other pathways, such as EGFR or ALK mutations. Zuragard's mechanism of action is novel in its direct inhibition of AKR4, thereby disrupting downstream signaling cascades essential for tumor growth. Preclinical studies indicate a synergistic effect when combined with existing chemotherapy regimens, suggesting potential for expanded indications and combination therapy strategies.

WHAT IS THE INTELLECTUAL PROPERTY LANDSCAPE SURROUNDING ZURAGARD?

The intellectual property portfolio for Zuragard is robust, with key patents providing market exclusivity.

• Composition of Matter Patents: U.S. Patent No. 9,XXX,XXX and EP Patent No. 3,XXX,XXX, expiring in 2035 and 2033 respectively, cover the fundamental chemical structure of Zuragard.
• Method of Use Patents: Multiple patents, including U.S. Patent No. 10,XXX,XXX, expiring in 2038, claim specific therapeutic applications for Zuragard in NSCLC, particularly in combination with other agents.
• Formulation Patents: Patents for novel drug delivery systems and optimized formulations are pending, aiming to extend exclusivity through 2040.

The company has also filed for regulatory exclusivities in the United States (5-year) and Europe (10-year) upon market approval.

WHAT ARE THE CLINICAL TRIAL RESULTS AND SAFETY PROFILE OF ZURAGARD?

Trial Phase	Study Design	Patient Population	Primary Endpoint	Key Results
Phase IIb	Randomized, double-blind, placebo-controlled	Advanced NSCLC with Biomarker X expression, pre-treated	Objective Response Rate (ORR)	ORR: 55% vs. 18% (placebo), p < 0.001
Phase III	Randomized, double-blind, placebo-controlled	Advanced NSCLC with Biomarker X expression, pre-treated	Progression-Free Survival (PFS)	Median PFS: 14.2 months vs. 7.5 months (placebo), Hazard Ratio (HR) 0.58, p < 0.001
Phase III	Randomized, double-blind, placebo-controlled	Advanced NSCLC with Biomarker X expression, pre-treated	Overall Survival (OS) (secondary endpoint)	Median OS: 28.5 months vs. 19.8 months (placebo), HR 0.65, p = 0.008; 24-month OS: 45% vs. 28%

The safety profile of Zuragard in clinical trials has been generally manageable. The most common adverse events (AEs) reported in Phase III trials (occurring in >20% of patients) include:

• Fatigue: 45%
• Nausea: 32%
• Diarrhea: 28%
• Hypertension: 25%
• Rash: 22%

Grade 3 or higher AEs reported in >5% of patients include neutropenia (8%), pneumonia (6%), and elevated liver enzymes (5%). Management strategies for these AEs have been established, and patient discontinuation rates due to AEs were 12% in the Zuragard arm compared to 7% in the placebo arm.

WHAT IS THE COMPETITIVE LANDSCAPE FOR ZURAGARD?

The competitive landscape for advanced NSCLC is dynamic. Zuragard will face competition from:

• Approved Targeted Therapies: Drugs targeting EGFR, ALK, ROS1, and other common mutations. While Zuragard targets a distinct pathway, some patients may have co-mutations or sequential progression on these therapies.
• Immunotherapies: Checkpoint inhibitors (e.g., pembrolizumab, nivolumab) are standard of care, particularly for patients with higher PD-L1 expression. Zuragard is being evaluated in combination with a checkpoint inhibitor in ongoing Phase II trials.
• Chemotherapy: Platinum-based doublet chemotherapy remains a backbone for many NSCLC patients.
• Emerging AKR4 Inhibitors: At least two other companies are developing AKR4 inhibitors, though they are at earlier stages of clinical development (Phase I/II).

Zuragard's key competitive advantages include its novel mechanism of action, demonstrated efficacy in a defined patient subset, and potential for combination therapy, which could differentiate it from single-target therapies.

WHAT ARE THE MANUFACTURING AND SUPPLY CHAIN CONSIDERATIONS?

The manufacturing process for Zuragard is a multi-step chemical synthesis requiring specialized expertise and stringent quality control. The company has secured manufacturing partnerships with Contract Development and Manufacturing Organizations (CDMOs) with a proven track record in small molecule API production.

• Current Capacity: Sufficient to support ongoing Phase III trials and initial launch quantities.
• Scalability: Plans are in place for significant capacity expansion through additional CDMO partnerships to meet projected peak demand.
• Raw Material Sourcing: Key starting materials are sourced from multiple qualified suppliers to mitigate supply chain risks. Lead times for critical raw materials are managed through strategic inventory buffering.

The stability profile of Zuragard under various storage conditions meets regulatory requirements. Packaging and labeling are designed to ensure product integrity and patient safety.

WHAT IS THE PRICING AND MARKET ACCESS STRATEGY FOR ZURAGARD?

The proposed pricing strategy for Zuragard targets a premium within the oncology market, reflecting its novel mechanism, demonstrated clinical benefit, and the unmet need it addresses.

• Projected Annual Treatment Cost: $150,000 - $175,000 USD.
• Value-Based Pricing Arguments: Supported by improved PFS and OS, reduced hospitalizations compared to some older therapies, and potential for improved quality of life.
• Market Access Efforts: Proactive engagement with payers and health technology assessment (HTA) bodies in key markets (U.S., EU5) to demonstrate pharmacoeconomic value. This includes the development of detailed health economic models and real-world evidence generation plans.
• Patient Access Programs: Establishment of co-pay assistance programs and free drug programs for eligible uninsured or underinsured patients.

The company anticipates achieving favorable formulary placement in major markets based on the robust clinical data.

WHAT IS THE SALES AND MARKETING STRATEGY FOR ZURAGARD?

The sales and marketing strategy for Zuragard will focus on a targeted, multi-channel approach aimed at oncologists, pulmonologists, and key opinion leaders (KOLs).

• Sales Force: A dedicated specialty sales force of approximately 200 representatives in the U.S. and 150 in Europe, with expertise in oncology and rare disease markets.
• KOL Engagement: Early and ongoing engagement with leading researchers and clinicians in NSCLC to build advocacy and disseminate clinical data.
• Medical Education: Comprehensive medical affairs programs including symposia, peer-reviewed publications, and dissemination of clinical trial data at major medical conferences (e.g., ASCO, ESMO).
• Digital Marketing: Targeted digital campaigns to healthcare professionals, focusing on data dissemination, disease state education, and patient identification tools.
• Patient Support Services: Integrated patient support services to assist with treatment adherence, manage side effects, and navigate access to care.

The launch will prioritize key markets where Biomarker X testing is established and reimbursement pathways are favorable.

WHAT ARE THE FINANCIAL PROJECTIONS AND PEAK SALES ESTIMATES FOR ZURAGARD?

Metric	Year 1 (Post-Launch)	Year 3	Year 5	Peak Sales (Year 7-8)
Prescriptions (Thousands)	15	60	130	250
Average Selling Price (ASP)	$160,000 (annualized)	$165,000	$170,000	$175,000
Net Revenue ($ Millions)	$2,000	$8,500	$19,000	$38,000
Gross Margin (%)	85	87	88	89
COGS ($ Millions)	$300	$1,105	$2,280	$4,180

Peak Sales Estimate: Approximately $2.5 billion annually. This estimate is based on:

• Addressable patient population (100,000+ annually in US/EU).
• Projected market penetration of 20-25% in the target biomarker-positive population by peak.
• Competitive pricing and market access assumptions.
• Potential for label expansion into first-line therapy or combination regimens.

These projections are sensitive to regulatory approval timelines, market access success, and competitive responses.

WHAT ARE THE KEY RISKS AND MITIGATION STRATEGIES?

Risk Category	Specific Risk	Mitigation Strategy
Clinical/Regulatory	Failure to achieve FDA/EMA approval, unexpected safety signals in late-stage trials.	Robust Phase III trial design, continuous safety monitoring, proactive regulatory engagement.
Market Access/Reimbursement	Stricter payer policies, unfavorable pricing negotiations, limited formulary access.	Comprehensive health economic data, early payer engagement, value-based contracting.
Competition	Entry of superior or lower-cost competing therapies, unexpected advancements by competitors.	Continued R&D for label expansion/combination therapies, strong IP protection, differentiation based on novel mechanism.
Manufacturing/Supply Chain	API production issues, raw material shortages, or quality control failures leading to supply disruption.	Diversified CDMO partnerships, redundant raw material sourcing, robust quality assurance systems.
Commercial Execution	Ineffective sales and marketing efforts, failure to achieve market penetration targets.	Experienced commercial leadership, targeted sales force deployment, robust medical education and KOL engagement.
Intellectual Property	Patent challenges or successful infringement by competitors.	Aggressive defense of existing patents, continuous monitoring of competitor IP, prosecution of new IP.
Biomarker Testing	Low adoption of Biomarker X testing by clinicians, leading to underdiagnosis and undertreatment.	Investment in diagnostic co-promotion, educational initiatives for pathologists and oncologists, development of companion diagnostics.

KEY TAKEAWAYS

• Zuragard demonstrates significant clinical benefit in a defined NSCLC patient population, justifying its premium pricing and targeted market entry.
• A strong intellectual property portfolio provides a foundation for market exclusivity through 2035-2040.
• The projected peak sales of $2.5 billion are achievable with successful market access and commercial execution.
• Mitigation strategies are in place to address key risks, including clinical, regulatory, and competitive challenges.
• Future growth potential exists through combination therapies and potential label expansions.

FREQUENTLY ASKED QUESTIONS

1. What is the projected timeline for Zuragard's regulatory submission and potential approval? The company anticipates submitting New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) and Marketing Authorisation Applications (MAAs) to the European Medicines Agency (EMA) in Q4 of the current year, with potential approval in late 2025 or early 2026.

2. How does Zuragard's safety profile compare to the current standard of care in its target indication? Zuragard's safety profile is generally comparable to other targeted therapies and immunotherapies in advanced NSCLC. While it has specific AEs such as hypertension and rash, these are manageable. The rates of severe AEs are within acceptable ranges for oncology therapeutics, and the benefit-risk profile is considered favorable based on Phase III data.

3. What is the strategy for expanding Zuragard's indication beyond its initial target? Ongoing Phase II trials are evaluating Zuragard in combination with a PD-1 inhibitor for first-line treatment of NSCLC patients with Biomarker X. Further studies are planned to explore its efficacy in other solid tumor types that express AKR4 or related pathways.

4. What is the estimated cost of goods sold (COGS) as a percentage of revenue at peak sales? COGS are projected to be approximately 11% of net revenue at peak sales, reflecting efficient manufacturing processes and economies of scale, contributing to high gross margins.

5. How reliant is Zuragard's success on the availability and adoption of a companion diagnostic for Biomarker X? Zuragard's success is highly reliant on the availability and widespread adoption of a companion diagnostic test for Biomarker X. The company is actively engaged in developing and commercializing a companion diagnostic in parallel with drug approval, and is investing in educational programs to drive testing uptake among clinicians.

CITED SOURCES

[1] Company investor relations materials. (2023). [2] Internal clinical trial data reports. (2024). [3] Market research analysis by [Specific Market Research Firm Name]. (2024). [4] U.S. Patent and Trademark Office database. (Accessed 2024). [5] European Patent Office database. (Accessed 2024). [6] Regulatory submission dossiers (confidential). (2024).